Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Vericel Corporation
Boehringer Ingelheim’s Head of Human Pharma Regions, Timmo Rousku Andersen shares with Scrip glimpses of his life and professional journey including distinct parallels between sports and leadership against the backdrop of the wider commercialization efforts for blockbuster therapy Jardiance.
The latest mega deals aimed at bringing Chinese innovation to the US have rekindled go-global hopes for a sector badly needing some cheer. But some investors say out-licensing may be the best route and that Chinese biotech must scale back its do-all mentality and focus on what it does best amid a new reality.
Leading Japanese firm reports solid growth in its fiscal nine months as it hints more may be to come after recent major deals to expand the mid- to late-stage pipeline and highlights progress for some key internal assets.
Yescarta surged ahead of competitors Kymriah and Breyanzi, helping Gilead’s oncology sales exceed $2bn, while the company reported the strongest sales in its HIV-dominated core business since 2015.
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
- Aastrom Biosciences, Inc.
- Genzyme Biosurgery
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.